#StopFakeMeds #ThinkSmart
In response to drug shortages, authorities are allowing pharmacists to compound certain medicines themselves. What was meant to be a temporary solution is gradually becoming standard practice.
But as supply disruptions persist, these so-called compounded preparations reveal a vulnerability: they facilitate the spread of fake medicines—through contamination, dosing errors, poor manufacturing or fraud. From the United States to India, Brazil, and Nigeria, these practices often lack oversight and clear regulation. The result: thousands of deaths linked to falsified drugs.
Widespread Regulatory Failures in the United States
Since 2022, GLP-1 drug shortages (Ozempic, Wegovy, Mounjaro) in the U.S. have led pharmacists to offer compounded alternatives. In April 2025, the FDA banned unverified compounded GLP-1 medications after a surge in reports of fakes including contaminated products.
In 2024–2025, Novo Nordisk and Eli Lilly detected dangerous impurities in products sold as genuine: bacteria, solvents, altered chemical structures.
This is not new. In 2012, the NECC compounding pharmacy triggered a deadly outbreak of fungal meningitis by distributing contaminated steroid injections—over 60 people died. The investigation uncovered illegal mass production under the guise of personalized compounding, inadequate sterilization, and document falsification.
These failures persist because compounded preparations are largely exempt from strict FDA controls: no marketing authorization, no clinical trials, no industrial-level traceability. Since 2013, only voluntarily registered facilities (503B) are inspected. Most local pharmacies (503A) remain under inconsistent state-level regulation.
Similar Weaknesses in India, Brazil, and Nigeria
In these countries, compounded drugs are often made without proper authorization or at large scale, frequently under poorly monitored conditions. They are sometimes used as cover to distribute fake medicines on loosely controlled markets.
France: Stricter Oversight, but a Growing Risk
In May 2025, France authorized pharmacists to compound sertraline, a widely used antidepressant in shortage, without requiring a new prescription.
From November 2024 to March 2025, 40 pharmacies were allowed to prepare pediatric amoxicillin to address supply gaps.
And in early 2025, more than 45,000 compounded doses of quetiapine (an antipsychotic) were produced to ensure continuity of care.
Although the regulatory framework in France is more robust—nominative prescriptions, good compounding practices, ANSM oversight—the growing reliance on these preparations, even when well controlled, risks becoming systemic. The ANSM has already suspended certain compounded medicines deemed unjustified or non-compliant.
Even with strict supervision, widespread use of compounded preparations can open the door to dangerous deviations. Without strict oversight and increased vigilance, these practices serve the interests of fake medicines network at the price of our health, and our lives.
